Immunomodulatory properties of antifungal agents on phagocytic cells

Immunological Investigations

Volumn 40, Issue 7-8, 2011, Pages 809-824

  Simitsopoulou, Maria ^a   Roilides, Emmanuel ^a   Walsh, Thomas J ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Antifungal agents; Immunopharmacology; Phagocytic cells

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CHEMOKINE; CORTICOSTEROID; CYTOKINE; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE;

CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FUNGUS; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ANIMALS; ANTIFUNGAL AGENTS; CYTOKINES; FUNGI; HUMANS; IMMUNOLOGIC FACTORS; MICE; MYCOSES; PHAGOCYTES; RECEPTORS, PATTERN RECOGNITION;

EID: 80053948951     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2011.615877     Document Type: Review

References (72)

1. Anderson J.B.(2005).Evolution of antifungal-drug resistance: mechanisms and pathogen fitness.Nat.Rev.Microbiol.3(7):547-556. (Pubitemid 40903878)
2. Antachopoulos C.Roilides E.(2005).Cytokines and fungal infections.Br.J.Haematol.129(5):583-596. (Pubitemid 40825819)
3. Ballesta S.Garcia I.Perea E.J.Pascual A.(2005).Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes.J.Antimicrob. Chemother.55(5):785-787. (Pubitemid 40691863)
4. Baltch A.L.Bopp L.H.Smith R.P.Ritz W.J.Carlyn C.J.Michelsen P.B.(2005).Effects of voriconazole granulocyte-macrophage colony-stimulating factor and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages.Diagn. Microbiol.Infect.Dis.52(4):299-304. (Pubitemid 41297567)
5. Baltch A.L.Bopp L.H.Smith R.P.Ritz W.J.Michelsen P.B.(2008).Anticandidal effects of voriconazole and caspofungin singly and in combination against Candida glabrata extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes.J.Antimicrob. Chemother.62(6):1285-1290.
6. Bellocchio S.Gaziano R.Bozza S.Rossi G.Montagnoli C.Perruccio K.Calvitti M.Pitzurra L.Romani L.(2005).Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.J.Antimicrob.Chemother.55(2):214-222. (Pubitemid 40331148)
7. Blanco J.L.Garcia M.E.(2008).Immune response to fungal infections.Vet.Immunol.Immunopathol.125(1-2):47-70.
8. Bopp L.H.Baltch A.L.Ritz W.J.Michelsen P.B.Smith R.P.(2006).Antifungal effect of voriconazole on intracellular Candida glabrata Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.J.Med.Microbiol.55(Pt 7):865-870. (Pubitemid 43974692)
9. Chiller T.Farrokhshad K.Brummer E.Stevens D.A.(2002).Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans.Med.Mycol.40(1): 21-26. (Pubitemid 34168304)
10. Choi J.H.Brummer E.Stevens D.A.(2004).Combined action of micafungin a new echinocandin and human phagocytes for antifungal activity against Aspergillus fumigatus.Microbes Infect.6(4):383-389. (Pubitemid 38393819)
11. Choi J.H.Kwon E.Y.Park C.M.Choi S.M.Lee D.G.Yoo J.H.Shin W.S.and Stevens D.A.(2010).Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia.Med.Mycol.48(5):704-709.
12. Cleary J.D.Rogers P.D.Chapman S.W.(2001).Differential transcription factor expression in human mononuclear cells in response to amphotericin B: identification with complementary DNA microarray technology.Pharmacotherapy 21(9):1046-1054. (Pubitemid 32807865)
13. Dotis J.Simitsopoulou M.Dalakiouridou M.Konstantinou T.Panteliadis C.Walsh T.J.Roilides E.(2008).Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus.J.Antimicrob.Chemother.61(4): 810-817. (Pubitemid 351426064)
14. Dotis J.Simitsopoulou M.Dalakiouridou M.Konstantinou T.Taparkou A.Kanakoudi-Tsakalidou F.Walsh T.J.Roilides E.(2006).Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.Antimicrob.Agents Chemother.50(3):868-873. (Pubitemid 43327788)
15. Ellis M.(2000).Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? Transpl.Infect.Dis.2(2):51-61. (Pubitemid 30262723)
16. Frank U.Greiner M.Engels I.Daschner F.D.(2004).Effects of caspofungin (MK- 0991) and anidulafungin (LY303366) on phagocytosis oxidative burst and killing of Candida albicans by human phagocytes.Eur.J.Clin.Microbiol.Infect.Dis. 23(9):729-731. (Pubitemid 39304331)
17. Gallagher J.C.MacDougall C.Ashley E.S.Perfect J.R.(2004).Recent advances in antifungal pharmacotherapy for invasive fungal infections.Expert.Rev.Anti- Infect.Ther.2(2):253-268. (Pubitemid 38735769)
18. Gil-Lamaignere C.Roilides E.Maloukou A.Georgopoulou I.Petrikkos G.Walsh T.J.(2002).Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum.J.Antimicrob.Chemother.50(6):1027-1030. (Pubitemid 36032827)
19. Graybill J.R.Bocanegra R.Luther M.(1995).Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis.Eur.J.Clin.Microbiol.Infect.Dis.14(8):700-703.
20. Graybill J.R.Bocanegra R.Najvar L.K.Loebenberg D.Luther M.F.(1998).Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression.Antimicrob.Agents Chemother.42(10):2467-2473. (Pubitemid 28462881)
21. Hamad M.(2008).Antifungal immunotherapy and immunomodulation: a doublehitter approach to deal with invasive fungal infections.Scand.J.Immunol. 67(6): 533-543. (Pubitemid 351677410)
22. Herrmann J.L.Dubois N.Fourgeaud,M.Basset D.Lagrange P.H.(1994).Synergic inhibitory activity of amphotericin-B and gamma interferon against intracellular Cryptococcus neoformans in murine macrophages.J.Antimicrob.Chemother.34(6): 1051-1058.
23. Hiemenz J.W.Walsh T.J.(1996).Lipid formulations of amphotericin B: recent progress and future directions.Clin.Infect.Dis.22 Suppl 2:S133-144. (Pubitemid 26256445)
24. Hohl T.M.Feldmesser M.Perlin D.S.Pamer E.G.(2008).Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal β-glucan exposure.J.Infect.Dis.198(2):176-185. (Pubitemid 352019282)
25. Jahn B.Rampp A.Dick C.Jahn A.Palmer M.Bhakdi S.(1998).Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level.Antimicrob.Agents Chemother.42(10):2569-2575. (Pubitemid 28462895)
26. Janes M.R.Fruman D.A.(2009).Immune regulation by rapamycin: moving beyond T cells.Sci.Signal 2(67):pe25.
27. Kimberg M.Brown G.D.(2008).Dectin-1 and its role in antifungal immunity.Med.Mycol.46(7):631-636.
28. Lamaris G.A.Lewis R.E.Chamilos G.May G.S.Safdar A.Walsh T.J.Raad II J.Kontoyiannis D.P.(2008).Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae.J.Infect.Dis.198(2):186-192. (Pubitemid 352019283)
29. Laniado-Laborin R.and Cabrales-Vargas M.N.(2009).Amphotericin B: side effects and toxicity.Rev.Iberoam.Micol.26(4):223-227.
30. Martin E.Stuben A.Gorz A.Weller U.Bhakdi S.(1994).Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.Antimicrob.Agents Chemother.38(1):13-22. (Pubitemid 24018151)
31. Matsuo K.Hotokezaka H.Ohara N.Fujimura Y.Yoshimura A.Okada Y.Hara Y.Yoshida N.Nakayama K.(2006).Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules.Microbiol.Immunol.50(4):337-347. (Pubitemid 46277500)
32. Mencacci A.Cenci E.Bacci A.Bistoni F.Romani L.(2000).Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis.J.Infect.Dis.181(2):686-694. (Pubitemid 30131840)
33. Morschhauser J.(2010).Regulation of multidrug resistance in pathogenic fungi.Fungal Genet.Biol.47(2):94-106.
34. Murphy E.A.Davis J.M.Carmichael M.D.(2010).Immune modulating effects of β-glucan.Curr.Opin.Clin.Nutr.Metab.Care 13(6):656-661.
35. Netea M.G.Van der Meer J.W.Kullberg B.J.(2006).Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence.Clin.Microbiol.Infect.12(5):404-409.
36. Pascual A.Garcia I.Conejo C.Perea E.J.(1993).Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes.Antimicrob.Agents Chemother.37(2):187-190. (Pubitemid 23046552)
37. Patera A.C.Menzel F.Jackson C.Brieland J.K.Halpern J.Hare R.Cacciapuoti A.Loebenberg D.(2004).Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.Antimicrob.Agents Chemother.48(8): 3154-3158. (Pubitemid 38989192)
38. Razonable R.R.Henault M.Lee L.N.Laethem C.Johnston P.A.Watson H.L.Paya C.V.(2005).Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2.Antimicrob.Agents Chemother.49(4):1617-1621. (Pubitemid 40463404)
39. Rodriguez M.M.Pastor F.J.Calvo E.Salas V.Sutton D.A.Guarro J.(2009).Correlation of in vitro activity serum levels and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.Antimicrob.Agents Chemother.53(12):5022-5025.
40. Rogers P.D.Jenkins J.K.Chapman S.W.Ndebele K.Chapman B.A.Cleary J.D.(1998).Amphotericin B activation of human genes encoding for cytokines.J.Infect.Dis.178(6):1726-1733. (Pubitemid 28558146)
41. Rogers P.D.Kramer R.E.Chapman S.W.Cleary J.D.(1999).Amphotericin B-induced interleukin-1beta expression in human monocytic cells is calcium and calmodulin dependent.J.Infect.Dis.180(4):1259-1266. (Pubitemid 30070212)
42. Rogers P.D.Pearson M.M.Cleary J.D.Sullivan D.C.Chapman S.W.(2002).Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis.J.Antimicrob.Chemother.50(6):811-817. (Pubitemid 36032799)
43. Rogers P.D.Stiles J.K.Chapman S.W.Cleary J.D.(2000).Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1.J.Infect.Dis.182(4):1280-1283.
44. Roilides E.Lyman C.A.Filioti J.Akpogheneta O.Sein T.Lamaignere C.G.Petraitiene R.Walsh T.J.(2002).Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.Antimicrob.Agents Chemother.46(6):1974-1976. (Pubitemid 34535224)
45. Roilides E.Lyman C.A.Panagopoulou P.Chanock S.(2003).Immunomodulation of invasive fungal infections.Infect.Dis.Clin.North Am.17(1):193-219. (Pubitemid 36514576)
46. Roilides E.Walsh T.(2004).Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp.Med.Mycol.42(1):1-13. (Pubitemid 38180418)
47. Romani L.(2004).Immunity to fungal infections.Nat.Rev.Immunol.4(1):1-23.
48. Safdar A.Shelburne S.A.Evans S.E.Dickey B.F.(2009).Inhaled therapeutics for prevention and treatment of pneumonia.Expert Opin.Drug Saf.8(4):435-449.
49. Salvenmoser S.Seidler M.J.Dalpke A.Muller F.M.(2010).Effects of caspofungin Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSFstimulated PMNs.FEMS Immunol.Med.Microbiol.60(1):74-77.
50. Sau K.Mambula S.S.Latz E.Henneke P.Golenbock D.T.Levitz S.M.(2003).The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism.J.Biol.Chem.278(39):37561- 37568. (Pubitemid 37175278)
51. Saxena S.Bhatnagar P.K.Ghosh P.C.Sarma P.U.(1999).Effect of amphotericin B lipid formulation on immune response in aspergillosis.Int.J.Pharm.188(1):19- 30. (Pubitemid 29472456)
52. Simitsopoulou M.Gil-Lamaignere C.Avramidis N.Maloukou A.Lekkas S.Havlova E.Kourounaki L.Loebenberg D.Roilides E.(2004).Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.Antimicrob. Agents Chemother.48(10):3801-3805. (Pubitemid 39304606)
53. Simitsopoulou M.Roilides E.Dotis J.Dalakiouridou M.Dudkova F.Andreadou E.Walsh T.J.(2005).Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.Antimicrob Agents Chemother.49(4):1397-1403. (Pubitemid 40463368)
54. Simitsopoulou M.Roilides E.Georgiadou E.Paliogianni F.Walsh T.J.(2011).Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus.Med.Mycol.49(2):176-185.
55. Simitsopoulou M.Roilides E.Maloukou A.Gil-Lamaignere C.Walsh T.J.(2008a).Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.Mycoses 51(2):147-154. (Pubitemid 351191114)
56. Simitsopoulou M.Roilides E.Paliogianni F.Likartsis C.Ioannidis J.Kanellou K.Walsh T.J.(2008b).Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors.Antimicrob.Agents Chemother.52(9):3301-3306.
57. Sorrell T.C.Chen S.C.(2009).Fungal-derived immune modulating molecules.Adv.Exp.Med.Biol.666:108-120.
58. Steinbach W.J.Stevens D.A.(2003).Review of newer antifungal and immunomodulatory strategies for invasive Aspergillosis.Clin.Infect.Dis.37 Suppl 3: S157-187. (Pubitemid 37260461)
59. Stevens D.A.Kullberg B.J.Brummer E.Casadevall A.Netea M.G.Sugar A.M.(2000).Combined treatment: antifungal drugs with antibodies cytokines or drugs.Med.Mycol.38 Suppl 1:305-315. (Pubitemid 32094078)
60. Swenson C.E.Perkins W.R.Roberts P.Ahmad I.Stevens R.Stevens D.A.Janoff A.S.(1998).In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob.Agents Chemother.42(4): 767-771. (Pubitemid 28216351)
61. Tohyama M.Kawakami K.Saito A.(1996).Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide.Antimicrob.Agents Chemother.40(8):1919-1923. (Pubitemid 26277816)
62. Turtinen L.W.Bremer L.A.Prall D.N.Schwartzhoff J.Hartsel S.C.(2005).Distinct cytokine release profiles from human endothelial and THP-1 macrophagelike cells exposed to different amphotericin B formulations. Immunopharmacol.Immunotoxicol.27(1):85-93. (Pubitemid 40389452)
63. Turtinen L.W.Croswell A.Obr A.(2008).Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations.J.Chemother.20(3):327-335. (Pubitemid 351998894)
64. Turtinen L.W.Prall D.N.Bremer L.A.Nauss R.E.Hartsel S.C.(2004).Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations.Antimicrob.Agents Chemother.48(2):396-403. (Pubitemid 38141694)
65. Vautier S.Sousa Mda G.Brown G.D.(2010).C-type lectins fungi and Th17 responses.Cytokine Growth Factor Rev.21(6):405-412.
66. Villar C.C.Dongari-Bagtzoglou A.(2008).Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis.Expert Rev.Mol.Med.10:e29.
67. Vora S.Chauhan S.Brummer E.Stevens D.A.(1998).Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.Antimicrob Agents Chemother 42(9):2299-2303. (Pubitemid 28420368)
68. Wellington M.Dolan K.Krysan D.J.(2009).Live Candida albicans suppresses production of reactive oxygen species in phagocytes.Infect.Immun.77(1):405-413.
69. Wheeler R.T.Kombe D.Agarwala S.D.Fink G.R.(2008).Dynamic morphotypespecific Candida albicans β-glucan exposure during infection and drug treatment.PLoS Pathog.4(12):e1000227.
70. Willment J.A.Brown G.D.(2008).C-type lectin receptors in antifungal immunity.Trends Microbiol.16(1):27-32.
71. Yamamoto M.Takeda K.(2010).Current views of toll-like receptor signaling pathways.Gastroenterol.Res.Pract.2010:240-365.
72. Zelante T.Bozza S.De Luca A.D'Angelo C.Bonifazi P.Moretti S.Giovannini G.Bistoni F.and Romani L.(2009).Th17 cells in the setting of Aspergillus infection and pathology.Med.Mycol.47 Suppl 1:S162-169.